Katey Enfield

Assistant Professor

The University of British Columbia
Country flagCanada

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (25)

Tobacco smoking accounts for nearly 90% of lung cancer deaths worldwide, yet the mechanisms underlying persistent cancer risk in former smokers are not fully understood. Epidemiological evidence shows that more than 40% of lung cancers develop over 15 years after cessation, demonstrating that while some smoking-induced molecular alterations resolve rapidly, others remain as long-lasting scars that promote carcinogenesis. This review synthesizes longitudinal and cross-sectional genomic, epigenomic, and transcriptomic studies of airway and lung tissues to distinguish persistent from nonpersistent smoking-induced molecular alterations. Persistent alterations include somatic mutations in TP53 and KRAS, DNA methylation at tumor suppressor loci, dysregulated noncoding RNAs, chromosomal instability, and epigenetic age acceleration. Nonpersistent changes, such as acute inflammatory responses and detoxification pathways, generally normalize within months to several years following cessation. Multi-omics profiling reveals coordinated patterns of dysregulation consistent with field cancerization in former smokers. In addition, the integration of multi-omics data with artificial intelligence may enable composite molecular signatures for stratifying high-risk former smokers, link molecular persistence to clinical outcomes, and inform chemoprevention strategies. Collectively, these observations clarify which molecular alterations sustain long-term cancer risk despite smoking cessation and highlight opportunities for precision prevention and earlier detection in high-risk populations.

Year:

2026

Background/Objectives: Non-small cell lung cancer (NSCLC) is the most common type of cancer, with lung adenocarcinoma (LUAD) as the predominant subtype. Despite advancements in targeted therapies, many NSCLC patients still experience poor outcomes due to treatment resistance and disease progression. Genomic instability (GI), a hallmark of cancer, defined as the increased tendency of DNA mutations and alterations, is closely linked to cancer initiation, progression, and resistance to therapy. Emerging evidence suggests that long non-coding RNAs (lncRNAs)—molecules longer than 200 nucleotides that do not encode proteins but regulate gene expression—play critical roles in cancer biology and are associated with GI. However, the relationship between GI and lncRNA expression in LUAD remains poorly understood. Methods: In this study, we analyzed the transcript profiles of lncRNAs and mRNAs from LUAD samples in The Cancer Genome Atlas (TCGA) database and classified them based on their Homologous Recombination Deficiency (HRD) score. The HRD score is an unweighted sum of three independent DNA-based measures of genomic instability: loss of heterozygosity, telomeric allelic imbalance, and large-scale transitions. We then performed a differential gene expression analysis to identify lncRNAs and mRNAs that were either upregulated or downregulated in samples with high HRD scores compared to those with low HRD scores. Following this, we conducted a correlation analysis to assess the significance of the association between HRD scores and the expression of both lncRNAs and mRNAs. Results: We identified 30 differentially expressed lncRNAs and 200 mRNAs associated with genomic instability. Using an RNA interactome database from sequencing experiments, we found evidence of interactions between GI-associated lncRNAs (GI-lncRNAs) and GI-associated mRNAs (GI-mRNAs). Further investigation showed that some GI-lncRNAs play regulatory and functional roles in LUAD and other diseases. We also found that GI-lncRNAs have potential as prognostic biomarkers, particularly when integrated with HRD stratification. The expression of specific GI-lncRNAs was associated with primary therapy response and immune infiltration in LUAD. Additionally, we identified existing drugs that could modulate GI-lncRNAs, offering potential therapeutic strategies to address GI in LUAD. Conclusions: Our findings suggest that GI-associated lncRNAs could serve as valuable biomarkers for LUAD prognosis and therapeutic response. Furthermore, modulating these lncRNAs presents potential treatment avenues to address genomic instability in LUAD.

Year:

2025

Beyond tertiary lymphoid structures, a significant number of immune-rich areas without germinal center-like structures are observed in non–small cell lung cancer. Here, we integrated transcriptomic data and digital pathology images to study the prognostic implications, spatial locations, and constitution of immune rich areas (immune hotspots) in a cohort of 935 patients with lung cancer from The Cancer Genome Atlas. A high intratumoral immune hotspot score, which measures the proportion of immune hotspots interfacing with tumor islands, was correlated with poor overall survival in lung squamous cell carcinoma but not in lung adenocarcinoma. Lung squamous cell carcinomas with high intratumoral immune hotspot scores were characterized by consistent upregulation of B-cell signatures. Spatial statistical analyses conducted on serial multiplex IHC slides further revealed that only 4.87% of peritumoral immune hotspots and 0.26% of intratumoral immune hotspots were tertiary lymphoid structures. Significantly lower densities of CD20 + CXCR5 + and CD79b + B cells and less diverse immune cell interactions were found in intratumoral immune hotspots compared with peritumoral immune hotspots. Furthermore, there was a negative correlation between the percentages of CD8 + T cells and T regulatory cells in intratumoral but not in peritumoral immune hotspots, with tertiary lymphoid structures excluded. These findings suggest that the intratumoral immune hotspots reflect an immunosuppressive niche compared with peritumoral immune hotspots, independent of the distribution of tertiary lymphoid structures. A balance toward increased intratumoral immune hotspots is indicative of a compromised antitumor immune response and poor outcome in lung squamous cell carcinoma. Significance: Intratumoral immune hotspots beyond tertiary lymphoid structures reflect an immunosuppressive microenvironment, different from peritumoral immune hotspots, warranting further study in the context of immunotherapies.

Year:

2025

Understanding the role of the tumor microenvironment (TME) in lung cancer is critical to improving patient outcomes. We identified four histology-independent archetype TMEs in treatment-naïve early-stage lung cancer using imaging mass cytometry in the TRACERx study (n = 81 patients/198 samples/2.3 million cells). In immune-hot adenocarcinomas, spatial niches of T cells and macrophages increased with clonal neoantigen burden, whereas such an increase was observed for niches of plasma and B cells in immune-excluded squamous cell carcinomas (LUSC). Immune-low TMEs were associated with fibroblast barriers to immune infiltration. The fourth archetype, characterized by sparse lymphocytes and high tumor-associated neutrophil (TAN) infiltration, had tumor cells spatially separated from vasculature and exhibited low spatial intratumor heterogeneity. TAN-high LUSC had frequent PIK3CA mutations. TAN-high tumors harbored recently expanded and metastasis-seeding subclones and had a shorter disease-free survival independent of stage. These findings delineate genomic, immune, and physical barriers to immune surveillance and implicate neutrophil-rich TMEs in metastasis. Significance: This study provides novel insights into the spatial organization of the lung cancer TME in the context of tumor immunogenicity, tumor heterogeneity, and cancer evolution. Pairing the tumor evolutionary history with the spatially resolved TME suggests mechanistic hypotheses for tumor progression and metastasis with implications for patient outcome and treatment. This article is featured in Selected Articles from This Issue, p. 897

Year:

2024

The growing scale and dimensionality of multiplexed imaging require reproducible and comprehensive yet user-friendly computational pipelines. TRACERx-PHLEX performs deep learning-based cell segmentation (deep-imcyto), automated cell-type annotation (TYPEx) and interpretable spatial analysis (Spatial-PHLEX) as three independent but interoperable modules. PHLEX generates single-cell identities, cell densities within tissue compartments, marker positivity calls and spatial metrics such as cellular barrier scores, along with summary graphs and spatial visualisations. PHLEX was developed using imaging mass cytometry (IMC) in the TRACERx study, validated using published Co-detection by indexing (CODEX), IMC and orthogonal data and benchmarked against state-of-the-art approaches. We evaluated its use on different tissue types, tissue fixation conditions, image sizes and antibody panels. As PHLEX is an automated and containerised Nextflow pipeline, manual assessment, programming skills or pathology expertise are not essential. PHLEX offers an end-to-end solution in a growing field of highly multiplexed data and provides clinically relevant insights.

Year:

2024

Beyond tertiary lymphoid structures, a significant number of immune rich areas without germinal center-like structures are observed in non-small cell lung cancer. Here, we integrated transcriptomic data and digital pathology images to study the prognostic implications, spatial locations, and constitution of immune rich areas (immune hotspots) in a cohort of 935 lung cancer patients from the TCGA. A high intratumoral immune hotspot score, which measures the proportion of immune hotspots interfacing with tumor islands, was correlated with poor overall survival in lung squamous cell carcinoma but not in lung adenocarcinoma. Lung squamous cell carcinomas with high intratumoral immune hotspot scores were characterized by consistent upregulation of B cell signatures. Spatial statistical analyses conducted on serial multiplex immunohistochemistry slides further revealed that only 4.87% of peritumoral immune hotspots and 0.26% of intratumoral immune hotspots were tertiary lymphoid structures. Significantly lower densities of CD20+CXCR5+ and CD79b+ B cells and less diverse immune cell interactions were found in intratumoral immune hotspots compared to peritumoral immune hotspots. Furthermore, there was a negative correlation between the percentages of CD8+ T cells and T regulatory cells in intratumoral but not in peritumoral immune hotspots, with tertiary lymphoid structures excluded. These findings suggest that the intratumoral immune hotspots reflect an immunosuppressive niche compared to peritumoral immune hotspots, independent of the distribution of tertiary lymphoid structures. A balance towards increased intratumoral immune hotspots is indicative of a compromised anti-tumor immune response and poor outcome in lung squamous cell carcinoma.

Year:

2024

IMC workflow defines the single-cell spatial landscape of the NSCLC tumor microenvironment. A, TRACERx 100 IMC cohort. We developed and applied two IMC antibody panels, Pan-immune and T cells and stroma, to tissue microarrays (TMA) from clinical samples collected at surgical resection (created with BioRender.com). B, Targets of antibodies described in this study. Bold text indicates targets detected in both IMC panels. C, IMC data were acquired from stained TMAs and processed to identify single cells and their phenotypes. D, 40,000 μm 2 crops of IMC images representing the markers from B with corresponding cell types from the pan-immune panel, unless annotated with an asterisk for the T cells and stroma panel only. E, A heat map of the z-score normalized median intensities of markers from the pan-immune panel across the identified cell subtypes. F, Proportion of major immune cell types identified in the pan-immune IMC data set per TMA core, calculated over the total tissue area (illustrated as blue and gold domains), tumor/epithelial compartment (gold domain), or the stromal compartment (blue domain). In two normal cores, the epithelial cell signal reflected very thin cells, which were not resolved into an epithelial compartment. All data from these cores are represented by the stroma compartment. Cell types color legend applies to D and F , where asterisks denote cell types identified in T cells and stroma panel only. LUAD, lung adenocarcinoma; LUSC, lung squamous cell carcinoma; NSCLC, non–small cell lung cancer; other, other non–small cell lung cancer histologies; IMC, imaging mass cytometry.

Year:

2024

Neutrophil infiltration is associated with recent subclonal expansion and poorer disease-free survival. A, Comparison of neutrophil cell density in primary tumors with metastasis-seeding clones detectable at time of surgery or during follow-up (metastasizing tumors) to tumors from patients who were metastasis-free and recurrence-free for more than 3 years of follow-up time (control) in LUAD ( n = 28) and LUSC ( n = 15) within the TRACERx discovery cohort. Maximum neutrophil density taken for tumors with multiple tumor cores. P values derived from one-tailed Wilcoxon test. B, Kaplan–Meier curves for DFS according to tumor-level TAN score in the validation cohort ( n = 332 patients). P value derived from univariate Cox model adjusted for histology. C, Multivariable Cox proportional hazard regression analysis of DFS using tumor-level TAN score and tumor-level necrosis evaluation from H&E images of diagnostic tumor blocks. D, Recent subclonal expansion score, measured as the maximum cancer cell fraction of subclones at the terminus of the phylogenetic tree, compared between TAN-high and TAN-low tumor regions in LUAD and LUSC patients from the TRACERx 421 cohort. P values were derived from a linear mixed effects model with patient as random effect. E, Spatial ITH score of cell types and communities and ITH probabilities of TME classes in multiregion analysis (pan-immune n = 41 tumors, 112 cores). ITH score was calculated as the average standard deviation of the cell/community density in multiple regions per tumor and z-score transformed. ITH score of αSMA + cells was derived from T cells and stroma panel ( n = 39 tumors, 105 cores). ITH probability was calculated as 1 − probability of all regions having the same indicated TME class. F, Example phylogenetic tree depicting a stage IIIA LUSC case with a clonal PIK3CA mutation, high TAN scores, and recent subclonal expansion, including in a region (R5) that seeded a lymph node (LN) metastasis (FLN, FFPE LN). The metastasis-seeding lineage is highlighted in orange. Tumor-level TAN scores and regional subclonal expansion (SubExp) scores are reported for primary tumor regions. The reported TAN score represents the maximum of the tumor nest and stroma scores. Each cluster in the phylogenetic tree is assigned a color that is also represented in the region clone maps. The clone maps illustrate the prevalence of each clone within a region. G, IMC images shown for R5 and the LN metastasis. Scale bar, 200 μm. H, Summary schematic of the link between tumors with a neutrophil enriched microenvironment with tumor progression. · , P P P P

Year:

2024

Supplementary Figures 1-22 with the corresponding figure legends inline. Supplementary Figure S1. TRACERx 100 imaging mass cytometry cohort. Supplementary Figure S2. Analysis of imaging mass cytometry data. Supplementary Figure S3. Characterisation of cell subtypes and spatial cellular communities in non-small cell lung cancer. Supplementary Figure S4. Clinicogenomic correlations with cell subtypes and communities. Supplementary Figure S5. TME class associations with cell types and clinical variables. Supplementary Figure S6. Cancer cell-intrinsic and -extrinsic features associated with immune cell infiltration. Supplementary Figure S7. Spatial, histological and metabolic features of the Tumour/Stroma:Neutrophil High TME class. Supplementary Figure S8. Transcriptomic features of TS:Neutrophil High TME class and Tumour-Associated Neutrophil scoring. Supplementary Figure S9. Somatic mutations in PIK3CA were associated with neutrophil recruitment through CXCL8 upregulation. Supplementary Figure S10. TAN score association with disease-free survival. Supplementary Figure S11. Validation of the prognostic association from the TAN scoring approach with an automated, deep learning approach in The Cancer Genome Atlas. Supplementary Figure S12. Imaging mass cytometry panel development. Supplementary Figure S13. Spillover matrices for imaging mass cytometry data. Supplementary Figure S14. Multiplexed Consensus Cell Segmentation. Supplementary Figure S15. Investigation of batch effects. Supplementary Figure S16. Raw pixel intensities. Supplementary Figure S17. Pathologist-guided labels. Supplementary Figure S18. Communities methodology and histology associations. Supplementary Figure S19. Multiplexed immunohistochemistry validation of checkpoint molecule expression. Supplementary Figure S20. Cell-cell relationships differ by TME class. Supplementary Figure S21. Cell-cell relationships differ by tumour genomics. Supplementary Figure S22. Cell-cell relationships based on tumour cell phenotypes.

Year:

2024

Neutrophil-rich TMEs are associated with activating mutations in PI3K and tumor-intrinsic CXCL8 upregulation. A, Representative crops of tumor-level H&E images with low TAN scores in the tumor nest and stroma (left) and high TAN scores in the tumor nest and stroma (right), inferred as the proportion of the neutrophil area in tumor/stroma from the total tumor/stroma tissue area. Scale bar, 50 μm; 400× magnification. B, Neutrophil cell density as defined by IMC compared between region-level TAN-low versus TAN-high tumor cores based on H&E scores in LUAD and LUSC. C and D, Proportion of tumor cores with (mut) and without (wt) PIK3CA driver mutations compared between TS:Neutrophil high versus other TME classes combined ( C ) and region-level TAN-High versus TAN-Low cores ( D ) in LUSC. P values were derived from a Chi-square test. E, Neutrophil cell density by PIK3CA mutation status, points colored by TME class assignment. F and G, TMM expression values for CXCL8 compared by PIK3CA mutation status ( F ) and between TME classes ( G ) in LUSC. H, Immunofluorescence images of CXCL8 RNAscope multiplexed with antibody staining of pancytokeratin (panCK) or MPO in an LUSC tumor region with a TS:Neutrophil high TME and subclonal PIK3CA mutation, and an LUSC patient with multiple TAN-high tumor regions and a clonal PIK3CA mutation. panCK and MPO examples for CRUK0075:R2 illustrate the same region of interest, whereas different regions of interest are shown for CRUK0468:R6. Scale bar, 100 μm. P values for B and E were calculated in a linear mixed-effects model with patient as the random-effect covariate. P values in F and G were derived from a limma–voom differential expression analysis correcting for multiple regions per tumor. · , P P P P M -values; TS, tumor/stroma; TIL, tumor-infiltrating lymphocyte; MΦ, macrophage; TAN, tumor-associated neutrophils; H&E, hematoxylin and eosin; mt, mutant; wt, wild-type.

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Collaborators (18)

Philip Hobson

Deputy Head of Flow Cytometry

The Francis Crick Institute

UNITED KINGDOM
View details

Yinyin Yuan

Institute of Cancer Research Sutton

UNITED KINGDOM
View details

Mihaela Angelova

The Francis Crick Institute

UNITED KINGDOM
View details

Charles Swanton

Chief Clinician

-

UNITED KINGDOM
View details

Julian Downward

Associate Research Director

The Francis Crick Institute

UNITED KINGDOM
View details

Mariam Jamal-Hanjani

Group Leader and Thoracic Oncologist

University College London

UNITED KINGDOM
View details

Clare Puttick

The Francis Crick Institute

UNITED KINGDOM
View details

Hanyun Zhang

Garvan Institute of Medical Research

AUSTRALIA
View details

Selvaraju Veeriah

University College London

UNITED KINGDOM
View details

Krijn Dijkstra

The Netherlands Cancer Institute

NETHERLANDS
View details

JAMES READING

University College London

UNITED KINGDOM
View details

Allan Hackshaw

University College London

UNITED KINGDOM
View details

Shan E Ahmed Raza

Associate Professor

University of Warwick

UNITED KINGDOM
View details

Khalid AbdulJabbar

Institute of Cancer Research

UNITED KINGDOM
View details

John Le Quesne

Professor of Molecular Pathology

University of Glasgow

UNITED KINGDOM
View details

Sergio Quezada

University College London

UNITED KINGDOM
View details

Erik Sahai

The Francis Crick Institute

UNITED KINGDOM
View details

Mary Green

Deputy Head of Experimental Histopathology

The Francis Crick Institute

UNITED KINGDOM
View details